Benefits and risks of combination therapy for hepatitis B
Open Access
- 27 April 2009
- journal article
- meeting report
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 49 (S5), S122-S128
- https://doi.org/10.1002/hep.22921
Abstract
In successful antiviral therapy of hepatitis B, drug combinations, particularly combinations without cross-resistance, can delay or prevent the emergence of drug-resistant mutants. Because drug-resistant mutants are archived and may limit future therapeutic options, prevention is important for long-term therapeutic efficacy. Additionally, combining drugs may achieve synergistic or additive antiviral effects compared with single drug therapy. Undesirable aspects of combination therapy include higher treatment costs and possibly lower adherence rates (due to pill number or complexity of regimen). Potentially harmful effects of combination therapy include higher rates of side effects, reduced efficacy due to drug competition, and the risk of multidrug-resistant hepatitis B virus (HBV) if combination therapy is insufficient to prevent resistance. Combination therapy has been shown to reduce the rate of drug resistance in chronic hepatitis B, but only when drugs with a low barrier to resistance are used (lamivudine, adefovir). Combination therapies may achieve greater degrees of HBV DNA suppression, but this has not been associated with higher rates of seroconversion (hepatitis B e antigen or hepatitis B surface antigen) compared to single drug therapy. The benefit of combination therapy has yet to be demonstrated with agents that are associated with a high barrier to resistance (tenofovir, entecavir). The use of combination therapy is recommended in specific patient groups: those with decompensated cirrhosis, those coinfected with human immunodeficiency virus and HBV who are on antiretroviral therapy, those who have undergone liver transplantation, and those with drug-resistant HBV infection. There is insufficient evidence to recommend combination therapy as first-line therapy for all patients with chronic hepatitis B. (HEPATOLOGY 2009;49:S122–S128.)Keywords
This publication has 34 references indexed in Scilit:
- A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in ThailandHepatology, 2008
- 256 Peginterferon Alpha-2a Plus Adefovir Dipivoxil vs. Peginterferon Alpha-2a Monotherapy for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Final Results of the PEG for B Randomized Multicenter TrialGastroenterology, 2008
- Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis BGut, 2007
- Virology of hepatitis B and C viruses and antiviral targetsJournal of Hepatology, 2006
- Randomized, Double-Blind Study of Emtricitabine (FTC) plus Clevudine versus FTC Alone in Treatment of Chronic Hepatitis BAntimicrobial Agents and Chemotherapy, 2006
- 116 A multicenter italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2-year analysis of 650 patientsJournal of Hepatology, 2006
- HBV drug resistance: Mechanisms, detection and interpretationJournal of Hepatology, 2006
- A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis BGastroenterology, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004